PROSPER: An observational study of Poteligeo in mycosis fungoides or Sezary syndrome

This prospective, observational study is looking at the use of Poteligeo in adults with mycosis fungoides (MF) or Sezary syndrome (SS).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05455931
 

Trial aim and background

The aim of this trial is to collect real-world information about the experiences of people with MF or SS and their carers who are being treated with Poteligeo. Examples of data which is to be collected is:

  • an understanding of treatment decisions
  • patient reported outcomes
  • disease and treatment experience

The hope is that it will demonstrate the full impact of treatment on patients and carers in real-world clinical practice.

Who can enter

Adults aged over 18 with a diagnosis of MF or SS who are about to start treatment with Poteligeo may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • Clatterbridge Hospital, Wirral
  • University Hospital Birmingham, Birmingham
  • The Christie NHS Foundation Trust, Manchester
  • Nottingham University Hospitals NHS Trust, Nottingham

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://beta.clinicaltrials.gov/study/NCT05455931

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.